Conceptio › Archive › ClinicalTrials.gov
ClinicalTrials.govpublic full text

Second-Line Sacituzumab Tirumotecan Plus Anlotinib for Advanced Driver Gene-Negative Non-Squamous NSCLC

Nanfang Hospital, Southern Medical University · 2025
ClinicalTrials.gov · Datasets · License: Public Domain · 2025
Open Source ↗
nsclc
nsclc (advanced non-small cell lung cancer), nsclc stage iiib~iv, second-line therapy, metastases, non-squamous non-small cell lung cancer, nsclc, egfr wild type, alk negative, advanced nsclc, second-line treatment, sacituzumab tirumotecan, anlotinib
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗
Record · ID 979982
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.